RECORD // Company

Advanced Biomed Inc.

Built 2026-11-21T23:53:53Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001213900-26-118899

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-989,0543 months ended 2026-09-3010-Q2026-11-120001213900-26-1188992026-11-21 23:53 UTCReport an error
Cash and cash equivalents$213,995at 2026-09-3010-Q2026-11-120001213900-26-1188992026-11-21 23:53 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001941029
Ticker
ADVB
CUSIP
00752P203
Record ID
sx:sec:0001941029

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

16 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-20SEC EDGAR company profile2026-11-21 23:53 UTCReport an error
SIC industry8071 Services-Medical Laboratories2026-11-20SEC EDGAR company profile2026-11-21 23:53 UTCReport an error
State of incorporationNV2026-11-20SEC EDGAR company profile2026-11-21 23:53 UTCReport an error
Fiscal year end (MMDD)06302026-11-20SEC EDGAR company profile2026-11-21 23:53 UTCReport an error
Business address401 RYLAND ST, STE 200-A, RENO, NV, 895022026-11-20SEC EDGAR company profile2026-11-21 23:53 UTCReport an error
ExchangesNasdaq2026-11-20SEC EDGAR company profile2026-11-21 23:53 UTCReport an error
Revenue (fiscal year ended 2026-06-30)$127,6372026-06-3010-K, XBRL Revenues2026-11-21 23:53 UTCReport an error
Net income (loss) (fiscal year ended 2026-06-30)$6,677,0772026-06-3010-K, XBRL NetIncomeLoss2026-11-21 23:53 UTCReport an error
Total assets (at 2026-06-30)$13,750,7162026-06-3010-K, XBRL Assets2026-11-21 23:53 UTCReport an error
Stockholders' equity (at 2026-06-30)$12,276,7272026-06-3010-K, XBRL StockholdersEquity2026-11-21 23:53 UTCReport an error
Cash and cash equivalents (at 2026-06-30)$385,5352026-06-3010-K, XBRL CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents2026-11-21 23:53 UTCReport an error
Operating cash flow (fiscal year ended 2026-06-30)$-1,946,9432026-06-3010-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 23:53 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-06-30)$31,6502025-06-3010-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 23:53 UTCReport an error
Operating lease liabilities (at 2025-06-30)$41,6902025-06-3010-K, XBRL OperatingLeaseLiability2026-11-21 23:53 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive (filed 2026-11-20)Agreement. On November 20, 2026, Advanced Biomed Inc., a Nevada Corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors (the “Investors”) relating to the issuance and sale of 320,000 shares of common stock (the “Purchased Shares”), par value $0.001 per share, of the Company (the “Common Stock”), at $0.35 per share for a total purchase price of $112,000 (the “Purchase Price”). The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Securities Purchase Agreements, which is filed as Exhibit 10.1 to this Current Report on Form…2026-11-20SEC EDGAR 8-K 0001213900-26-122692 (text as filed, excerpt)2026-11-21 23:53 UTCReport an error
8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-11-20)The information included in Item 1.01 of this Current Report is incorporated by reference into this Item 3.02 of this Current Report to the extent applicable. The Purchased Shares were issued in a private placement exempt from the registration requirements of the U.S. Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof and Regulation S promulgated thereunder.2026-11-20SEC EDGAR 8-K 0001213900-26-122692 (text as filed, excerpt)2026-11-21 23:53 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.